

ivermectin tablets (Stromectol[®], generics)

Policy # 00763

Original Effective Date: 01/01/2022

Current Effective Date: 02/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Based on review of available data, the Company may consider ivermectin tablets (Stromectol[®], generics)[†] for the treatment of intestinal (i.e., non-disseminated) strongyloidiasis, onchocerciasis, and other accepted compendia indications to be **eligible for coverage**.**

Patient Selection Criteria

Coverage eligibility for ivermectin tablets (Stromectol, generics) will be considered when the following criteria are met:

- Patient has a diagnosis of any of the following:
 - Intestinal (i.e., non-disseminated) strongyloidiasis due to the nematode parasite *Strongyloides stercoralis*; OR
 - Onchocerciasis due to the nematode parasite *Onchocerca volvulus*; OR
 - Ascariasis due to *Ascaris lumbricoides*; OR
 - Demodicosis due to *Demodex folliculorum* and *Demodex brevis*; OR
 - Enterobiasis (pinworm infection) due to *Enterobius vermicularis*; OR
 - Gnathostomiasis due to *Gnathostoma spinigerum*; OR
 - Hookworm-related cutaneous larva migrans; OR
 - Pediculosis caused by head (*pediculus humanus capitis*), body (*pediculus humanus corporis*), or pubic (*Phthirus pubis*) lice; OR
 - *Mansonella ozzardi* infection; OR
 - *Mansonella streptocerca* infection; OR
 - Scabies due to *Sarcoptes scabiei*; OR
 - Trichuriasis (whipworm infection) due to *Trichuris trichiura*; OR
 - *Wucheria bancrofti* infection; AND

ivermectin tablets (Stromectol[®], generics)

Policy # 00763

Original Effective Date: 01/01/2022

Current Effective Date: 02/01/2026

- If the request is for brand Stromectol: Patient has tried and failed (e.g., intolerance or inadequate response) the generic equivalent ivermectin tablets unless there is clinical evidence or patient history that suggests use of the generic equivalent will be ineffective or cause an adverse reaction to the patient; AND
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*
- If the request is for ivermectin 6 mg tablets: Patient has tried and failed (e.g., intolerance or inadequate response) ivermectin 3 mg tablets unless there is clinical evidence or patient history that suggests use of the ivermectin 3 mg tablets will be ineffective or cause an adverse reaction to the patient.
*(Note: This specific patient selection criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met)*

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of brand Stromectol when there is no clinical evidence or patient history that suggests the generic equivalent will be ineffective or cause an adverse reaction to the patient to be **not medically necessary**.**

Based on review of available data, the Company considers the use of ivermectin 6 mg tablets when there is no clinical evidence or patient history that suggests ivermectin 3 mg tablet will be ineffective or cause an adverse reaction to the patient to be **not medically necessary**.**

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of ivermectin tablets (Stromectol, generics) for any indication not listed in the patient selection criteria to be **investigational**.*

Background/Overview

Stromectol and its generic equivalent, ivermectin tablets, are indicated for the treatment of intestinal (i.e., non-disseminated) strongyloidiasis due to the nematode parasite *Strongyloides stercoralis*. They are also indicated for the treatment of onchocerciasis due to the nematode parasite *Onchocerca volvulus*. These products also have a large number of accepted compendia indications, as noted above in the patient selection criteria. Stromectol and its generic equivalent are available in 3 mg tablets, and dosing is typically based on body weight. Generic ivermectin is also available in a 6 mg tablet strength.

In 2021 during the COVID-19 pandemic, the Centers for Disease Control (CDC) released an official Health Advisory noting a rapid increase in ivermectin prescriptions and reports of severe illness associated with the use of ivermectin to prevent or treat COVID-19. The National Institutes of Health's (NIH) COVID-19 Treatment Guidelines Panel determined that there was insufficient data

ivermectin tablets (Stromectol[®], generics)

Policy # 00763

Original Effective Date: 01/01/2022

Current Effective Date: 02/01/2026

to recommend ivermectin for the treatment of COVID-19 and that more adequately powered, well-designed, and well-conducted trials are needed to provide more specific, evidence-based guidance. The Infectious Disease Society of America (IDSA) guidelines on the treatment of management of patients with COVID-19 reviewed studies from several clinical trials that assessed the efficacy of oral ivermectin in the treatment of COVID-19 (updated 2022). The IDSA currently recommends against the use of ivermectin for the treatment of COVID-19, except in clinical trials.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Stromectol and its generic equivalent, ivermectin tablets, are indicated for the treatment of intestinal (i.e., non-disseminated) strongyloidiasis due to the nematode parasite *Strongyloides stercoralis*. They are also indicated for the treatment of onchocerciasis due to the nematode parasite *Onchocerca volvulus*.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

The rationale behind this policy is to ensure that ivermectin tablet products are being appropriately utilized based on FDA approved indications or accepted compendia indications. This policy also ensures that the generic product is utilized, where possible, prior to the brand product and that the more cost effective strength of ivermectin 3 mg is utilized prior to the more expensive 6 mg tablet formulation.

References

1. Anthelmintic – Ivermectin Tablets Prior Authorization Policy. Express Scripts. Updated September 2021.
2. Stromectol tablets [package insert]. Whitehouse Station, New Jersey: Merck. Updated September 2024.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2020. Available at: <http://www.clinicalpharmacology-ip.com/Default.aspx>. Accessed on August 31, 2021. Search term: ivermectin.
4. Facts and Comparisons[®] Online. Wolters Kluwer Health, Inc.; 2020. Available at: <http://online.factsandcomparisons.com/login.aspx?url=/index.aspx&q=>. Accessed on August 31, 2021. Search term: ivermectin.
5. Centers for Disease Control and Prevention. Parasites - Onchocerciasis (also known as river blindness). Available at: <https://www.cdc.gov/parasites/onchocerciasis/>. Accessed on August 31, 2021.

ivermectin tablets (Stromectol[®], generics)

Policy # 00763

Original Effective Date: 01/01/2022

Current Effective Date: 02/01/2026

6. Centers for Disease Control and Prevention. Chapter 4. Travel-related infectious diseases. Available at: <https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/strongyloidiasis>. Accessed on August 31, 2021.
7. Micromedex[®] (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com/>. Accessed on August 31, 2021. Search term: ivermectin.
8. Centers for Disease Control and Prevention. Parasites – Ascariasis. Available at: <https://www.cdc.gov/parasites/ascariasis/index.html>. Accessed on August 31, 2021.
9. Centers for Disease Control and Prevention. Parasites – Gnathostomiasis. Available at: https://www.cdc.gov/parasites/gnathostoma/health_professionals/index.htm. Accessed on August 31, 2021.
10. Centers for Disease Control and Prevention. Parasites – Zoonotic Hookworm. Available at: https://www.cdc.gov/parasites/zoonotichookworm/health_professionals/index.html#tx. Accessed on August 31, 2021.
11. Centers for Disease Control and Prevention. Parasites – Head Lice. Available at: <https://www.cdc.gov/parasites/lice/head/index.html>. Accessed on August 31, 2021.
12. Centers for Disease Control and Prevention. Parasites – Body Lice. Available at: <https://www.cdc.gov/parasites/lice/body/treatment.html>. Accessed on August 31, 2021.
13. Centers for Disease Control and Prevention. Parasites – Pubic “Crab” Lice. Available at: <https://www.cdc.gov/parasites/lice/pubic/index.html>. Accessed on August 31, 2021.
14. Centers for Disease Control and Prevention. Parasites – Scabies. Available at: <https://www.cdc.gov/parasites/scabies/index.html>. Accessed on August 31, 2021.
15. Centers for Disease Control and Prevention. Parasites – Trichuriasis (also known as whipworm infection). Available at: https://www.cdc.gov/parasites/whipworm/health_professionals/index.html. Accessed on August 31, 2021.
16. Centers for Disease Control and Prevention. Parasites – Lymphatic filariasis. Available at: <https://www.cdc.gov/parasites/lymphaticfilariasis/>. Accessed on August 31, 2021.
17. Ta-Ting TH, Crainey JL, Post RJ, et al. Mansonellosis: current perspectives. *Res Rep Trop Med.* 2018;9:9-24.
18. Centers for Disease Control and Prevention – Emergency Preparedness and Response. Rapid increase in ivermectin prescriptions and reports of severe illness associated with use of products containing ivermectin to prevent or treat COVID-19. Distributed via the CDC Health Alert Network on August 26, 2021. Available at: https://emergency.cdc.gov/han/2021/pdf/CDC_HAN_449.pdf. Accessed on August 31, 2021.
19. IDSA Guidelines on the Treatment and Management of Patients with Covid-19. Available at: <https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/>. Accessed December 10, 2025.
20. UpToDate. Wolters Kluwer. Accessed on September 24, 2021. Search term: ivermectin.
21. Bhimraj A, Morgan RL, Nadig N, et al. IDSA guidelines on the treatment and management of patients with COVID-19. *Clin Infect Dis.* 2024;78(7): e250-e349.

ivermectin tablets (Stromectol[®], generics)

Policy # 00763

Original Effective Date: 01/01/2022

Current Effective Date: 02/01/2026

Policy History

Original Effective Date: 01/01/2022

Current Effective Date: 02/01/2026

10/07/2021	Medical Policy Committee review
10/13/2021	Medical Policy Implementation Committee approval. New policy.
10/06/2022	Medical Policy Committee review
10/11/2022	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/05/2023	Medical Policy Committee review
10/11/2023	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/03/2024	Medical Policy Committee review
10/08/2024	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
10/02/2025	Medical Policy Committee review
10/08/2025	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/05/2026	Medical Policy Committee review
01/07/2026	Medical Policy Implementation Committee approval. Added new strength of ivermectin 6 mg tablet with relevant criteria. Updated background section.

Next Scheduled Review Date: 01/2027

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 1. Consultation with technology evaluation center(s);
 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 3. Reference to federal regulations.

ivermectin tablets (Stromectol®, generics)

Policy # 00763

Original Effective Date: 01/01/2022

Current Effective Date: 02/01/2026

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan’s authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan’s pharmacy benefit.